• Explore /
  • Poster
  • / Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA.

Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA.

Abstract Poster

Authors

null

Reagan Barnett

Guardant Health, Inc., Redwood City, CA

Reagan Barnett , Sree M Lanka , Keelia M. Clemens , Lesli Ann Kiedrowski , Hani M. Babiker , Alan Haruo Bryce , Haley M. Meyer , Yujin Choi , Rohan Garje , Xin Gao , Richard Y. Chang , Albert Jang , Pat Gulhati , Mehmet Asim Bilen , Pedro C. Barata

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Circulating Biomarkers

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2561)

DOI

10.1200/JCO.2023.41.16_suppl.2561

Abstract #

2561

Poster Bd #

403

Abstract Disclosures

Similar Posters

First Author: Anwaar Saeed

First Author: Rebecca A Sager

First Author: Philip C. Mack

First Author: Tanya Jindal